A Comparative Analysis of Two Contrasting European Approaches for Rewarding the Value Added by Drugs...
A Comparative Analysis of Two Contrasting European Approaches for Rewarding the Value Added by Drugs for Cancer: England Versus France
About this item
Full title
Author / Creator
Publisher
Springer
Journal title
Language
English
Formats
Publication information
Publisher
Springer
Subjects
More information
Scope and Contents
Contents
Within Europe, contrasting approaches have emerged for rewarding the value added by new drugs. In Ireland, The Netherlands, Sweden and the UK, the price of, and access to, a new drug has to be justified by the health gain it delivers compared with current therapy, typically expressed in quality-adjusted life-years (QALYs) gained. By contrast, in Fr...
Alternative Titles
Full title
A Comparative Analysis of Two Contrasting European Approaches for Rewarding the Value Added by Drugs for Cancer: England Versus France
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_gale_infotracmisc_A714595983
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A714595983
Other Identifiers
ISSN
1170-7690
DOI
10.1007/s40273-014-0144-z
